RS61466B1 - Sastavi protiv raka - Google Patents
Sastavi protiv rakaInfo
- Publication number
- RS61466B1 RS61466B1 RS20210184A RSP20210184A RS61466B1 RS 61466 B1 RS61466 B1 RS 61466B1 RS 20210184 A RS20210184 A RS 20210184A RS P20210184 A RSP20210184 A RS P20210184A RS 61466 B1 RS61466 B1 RS 61466B1
- Authority
- RS
- Serbia
- Prior art keywords
- anticancer compositions
- anticancer
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196591 | 2014-12-05 | ||
| PCT/US2015/063667 WO2016090101A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
| EP15817642.0A EP3226842B1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61466B1 true RS61466B1 (sr) | 2021-03-31 |
Family
ID=52006905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210184A RS61466B1 (sr) | 2014-12-05 | 2015-12-03 | Sastavi protiv raka |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20170360707A1 (sr) |
| EP (2) | EP3226842B1 (sr) |
| JP (1) | JP6767368B2 (sr) |
| KR (1) | KR102348325B1 (sr) |
| CN (2) | CN106999430A (sr) |
| AR (1) | AR102924A1 (sr) |
| AU (1) | AU2015358493B2 (sr) |
| CA (1) | CA2969661C (sr) |
| CL (1) | CL2017001372A1 (sr) |
| CO (1) | CO2017005573A2 (sr) |
| CR (1) | CR20170217A (sr) |
| CY (1) | CY1123856T1 (sr) |
| DK (1) | DK3226842T3 (sr) |
| EA (1) | EA035988B1 (sr) |
| ES (1) | ES2839128T3 (sr) |
| HR (1) | HRP20201902T1 (sr) |
| HU (1) | HUE051888T2 (sr) |
| IL (1) | IL252324B (sr) |
| LT (1) | LT3226842T (sr) |
| MA (2) | MA41108B1 (sr) |
| MD (1) | MD3226842T2 (sr) |
| MX (1) | MX2017007201A (sr) |
| NI (1) | NI201700069A (sr) |
| PL (1) | PL3226842T3 (sr) |
| PT (1) | PT3226842T (sr) |
| RS (1) | RS61466B1 (sr) |
| SG (1) | SG11201704264UA (sr) |
| SI (1) | SI3226842T1 (sr) |
| TW (1) | TWI683662B (sr) |
| UA (1) | UA121123C2 (sr) |
| WO (1) | WO2016090101A1 (sr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2885415C (en) | 2012-09-26 | 2021-06-29 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| ES2883187T3 (es) | 2014-12-05 | 2021-12-07 | Aragon Pharmaceuticals Inc | Composiciones anticancerosas |
| EP3697398A1 (en) | 2017-10-16 | 2020-08-26 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| EP3773509B1 (en) | 2018-04-06 | 2023-11-01 | Capsugel Belgium NV | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
| WO2020144649A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising enzalutamide dispersed in apple sauce |
| CA3128331A1 (en) | 2019-01-30 | 2020-08-06 | Margaret K. YU | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| JP2022524289A (ja) | 2019-01-30 | 2022-05-02 | ヤンセン ファーマシューティカ エヌ．ベー． | 分子サブタイプに基づいて前立腺癌を治療する方法 |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| CN115666565A (zh) | 2019-11-04 | 2023-01-31 | 阿拉贡药品公司 | 用于治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂 |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03008999A (es) | 2001-04-02 | 2004-02-12 | Astrazeneca Ab | Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp. |
| WO2003077827A1 (fr) * | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Procede de production de medicament solide en dispersion |
| EP1694302A1 (en) * | 2003-12-15 | 2006-08-30 | Council of Scientific and Industrial Research | TASTE MASKED PHARMACEUTICAL COMPOSITIONS COMPRISING BITTER DRUG AND pH SENSITIVE POLYMER |
| PL2368550T3 (pl) * | 2006-03-27 | 2014-01-31 | Univ California | Modulator receptorów androgenowych do leczenia raka gruczołu krokowego i chorób związanych z receptorami androgenów |
| EP3124481B1 (en) * | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| US10071945B2 (en) * | 2011-06-15 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2013152342A1 (en) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| JP6182209B2 (ja) | 2012-06-07 | 2017-08-16 | アラゴン ファーマシューティカルズ，インコーポレイテッド | アンドロゲン受容体変調剤の結晶質形態 |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| CN105358535B (zh) * | 2012-09-11 | 2019-01-04 | 麦迪威森前列腺医疗有限责任公司 | 恩杂鲁胺制剂 |
| CA2885415C (en) * | 2012-09-26 | 2021-06-29 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| MY192032A (en) * | 2013-01-22 | 2022-07-24 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| RU2016104643A (ru) * | 2013-08-12 | 2017-09-19 | Токай Фармасьютикалз, Инк. | Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения |
| US20160346207A1 (en) * | 2014-02-05 | 2016-12-01 | Lek Pharmaceuticals D.D. | Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists |
-
2015
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro unknown
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active IP Right Grant
- 2015-12-03 CA CA2969661A patent/CA2969661C/en active Active
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/en active Application Filing
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 MX MX2017007201A patent/MX2017007201A/es unknown
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 CN CN202211487545.0A patent/CN115837010A/zh active Pending
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh active
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/en active Active
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-03 EP EP20209559.2A patent/EP3842034A1/en active Pending
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
-
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
-
2020
- 2020-11-30 HR HRP20201902TT patent/HRP20201902T1/hr unknown
-
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279833A (en) | Anti-cancer drugs | |
| IL252324A0 (en) | Anti-cancer drugs | |
| IL252325A0 (en) | Anti-cancer drugs | |
| GB201419257D0 (en) | Pharmaceutical compositions | |
| GB201618482D0 (en) | Pharmaceutical compositions | |
| IL249553A0 (en) | Pharmaceutical preparations | |
| IL263157A (en) | Anticancer compositions | |
| GB201703061D0 (en) | Polyphenol compositions | |
| IL251479A0 (en) | components | |
| GB201408167D0 (en) | Compositions | |
| IL250817A0 (en) | pharmaceutical preparations | |
| GB201420306D0 (en) | Compositions | |
| GB201419849D0 (en) | Compositions | |
| HUE036695T2 (hu) | Ubidekarenon készítmény | |
| GB201415634D0 (en) | Novel compositions | |
| GB202009707D0 (en) | Anti-adherant botanical compositions | |
| GB201406863D0 (en) | Compositions comprising variegin | |
| SG2014014872A (en) | Pharmaceutical compositions | |
| GB201408432D0 (en) | Pharmaceutical compositions | |
| GB201401510D0 (en) | Composition |